株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

免疫チェックポイント阻害剤の世界市場:2019年~2023年

Global Immune Checkpoint Inhibitors Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 754197
出版日 ページ情報 英文 116 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.20円で換算しております。
Back to Top
免疫チェックポイント阻害剤の世界市場:2019年~2023年 Global Immune Checkpoint Inhibitors Market 2019-2023
出版日: 2018年11月13日 ページ情報: 英文 116 Pages
概要

ますます多くの癌症例が世界中で診断されています。癌に関する意識を高め、疾患の早期発見を助けるために、様々な国際的および国内レベルのキャンペーンが実施されています。 Technavioのアナリストは、免疫チェックポイント阻害剤市場が2023年までに約3%のCAGRで成長すると予測しています。

当レポートでは、世界の免疫チェックポイント阻害剤市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 市場状況

  • 市場のエコシステム
  • 市場特性
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市場状況

第6章 市場セグメンテーション:タイプ別

  • 市場セグメンテーション:タイプ別(2018年~2023年)
  • 比較:タイプ別
  • PD-1阻害剤
  • CTLA-4阻害剤
  • その他
  • 市場機会:タイプ別

第7章 顧客情勢

第8章 地域別景観

  • 地域別セグメンテーション(2018年~2023年)
  • 地域別比較
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第11章 市場動向

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Pfizer

第14章 付録

  • 略語のリスト

第15章 TECHNAVIOについて

図表
  • Exhibit 01: Global oncology drugs market
  • Exhibit 02: Segments of global oncology drugs market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ billions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Type - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by type
  • Exhibit 19: PD-1 inhibitors - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 20: PD-1 inhibitors - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: CTLA-4 inhibitors - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 22: CTLA-4 inhibitors - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Others - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by type
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: Americas - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in Americas
  • Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 33: Patient assistance program by AstraZeneca
  • Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in EMEA
  • Exhibit 36: APAC - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 37: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in APAC
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Patient assistance programs
  • Exhibit 42: Combined action of PD-1 and CTLA-4 checkpoint inhibitors
  • Exhibit 43: Treatment costs of immune checkpoint inhibitor therapeutics in US
  • Exhibit 44: Side effects of immune checkpoint inhibitors
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Some of the strategic alliances in global immune checkpoint inhibitors market
  • Exhibit 47: Approved drugs with respect to their cancer indications
  • Exhibit 48: Expansion of research areas of approved drugs
  • Exhibit 49: Vendor landscape
  • Exhibit 50: Landscape disruption
  • Exhibit 51: Vendors covered
  • Exhibit 52: Vendor classification
  • Exhibit 53: Market positioning of vendors
  • Exhibit 54: AstraZeneca - Vendor overview
  • Exhibit 55: AstraZeneca - Business segments
  • Exhibit 56: AstraZeneca - Organizational developments
  • Exhibit 57: AstraZeneca - Geographic focus
  • Exhibit 58: AstraZeneca - Segment focus
  • Exhibit 59: AstraZeneca - Key offerings
  • Exhibit 60: AstraZeneca - Key customers
  • Exhibit 61: Bristol-Myers Squibb - Vendor overview
  • Exhibit 62: Bristol-Myers Squibb - Business segments
  • Exhibit 63: Bristol-Myers Squibb - Organizational developments
  • Exhibit 64: Bristol-Myers Squibb - Geographic focus
  • Exhibit 65: Bristol-Myers Squibb - Key offerings
  • Exhibit 66: Bristol-Myers Squibb - Key customers
  • Exhibit 67: F. Hoffmann-La Roche - Vendor overview
  • Exhibit 68: F. Hoffmann-La Roche - Business segments
  • Exhibit 69: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 70: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 71: F. Hoffmann-La Roche - Segment focus
  • Exhibit 72: F. Hoffmann-La Roche - Key offerings
  • Exhibit 73: F. Hoffmann-La Roche - Key customers
  • Exhibit 74: Merck Sharp & Dohme - Vendor overview
  • Exhibit 75: Merck Sharp & Dohme - Business segments
  • Exhibit 76: Merck Sharp & Dohme - Organizational developments
  • Exhibit 77: Merck Sharp & Dohme - Geographic focus
  • Exhibit 78: Merck Sharp & Dohme - Segment focus
  • Exhibit 79: Merck Sharp & Dohme - Key offerings
  • Exhibit 80: Merck Sharp & Dohme - Key customers
  • Exhibit 81: Pfizer - Vendor overview
  • Exhibit 82: Pfizer - Business segments
  • Exhibit 83: Pfizer - Organizational developments
  • Exhibit 84: Pfizer - Geographic focus
  • Exhibit 85: Pfizer - Segment focus
  • Exhibit 86: Pfizer - Key offerings
  • Exhibit 87: Pfizer - Key customers
目次
Product Code: IRTNTR30233

About this market

The growing number of cancer cases being diagnosed across the globe. Various international and national level campaigns are conducted to increase the awareness about cancer and to help early detection of the disease. Technavio's analysts have predicted that the immune checkpoint inhibitors market will register a CAGR of almost 3% by 2023.

Market Overview

High target affinity and specificity of immune checkpoint inhibitors drugs

Most of the approved therapies for cancer treatment have severe side effects, which lowers the patient compliance towards the treatment. Thus, these drawbacks help the immune checkpoint inhibitors market grow.

High costs associated with the treatment

Treatment cost is one of the major challenges for cancer patients. The high cost is mainly due to hospitalization, laboratory costs, and novel immunotherapies.

For the detailed list of factors that will drive and challenge the growth of the immune checkpoint inhibitors market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including AstraZeneca and Bristol-Myers Squibb the competitive environment is quite intense. Factors such as the high target affinity and specificity of immune checkpoint inhibitors drugs and the growing number of cancer cases being diagnosed across the globe will provide considerable growth opportunities to immune checkpoint inhibitors manufactures. AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and F. Hoffmann-La Roche are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.'

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • PD-1 inhibitors - Market size and forecast 2018-2023
  • CTLA-4 inhibitors - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Pfizer

PART 14: APPENDIX

  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

Back to Top